Valneva SE VALN
NASDAQ VALN
$6.89 -0.17 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Valneva SE (VALN) Cash from Financing Activities (2021 - 2026)

Valneva SE (VALN) posted Cash from Financing Activities of -$5.5 million for Q1 2026, up 49.64% sequentially from -$10.9 million in Q4 2025, and up 6.51% YoY from -$5.2 million in Q1 2025.

Analysis

Valneva SE (VALN) Cash from Financing Activities (2021 - 2026) Analysis & Trends

Valneva SE has reported Cash from Financing Activities for 6 years, with the latest figure at -$5.5 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 6.51% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195032.3 (down 100.54% YoY) and the FY2025 annual result came in at -$722871.0, down 102.18% from the prior year.
  • Cash from Financing Activities grew to -$5.5 million in Q1 2026 per VALN's latest filing, from -$10.9 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $10.3 billion in Q3 2023 and troughed at -$10.3 billion in Q2 2023.
  • A 5-year average of $18.7 million and a median of -$649994.6 in 2025 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 61612.28% in 2023, down 9392.38% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $95.4 million in 2022, then sank by 58.32% to $39.7 million in 2023, then sank by 112.34% to -$4.9 million in 2024, then tumbled by 122.23% to -$10.9 million in 2025, then soared by 49.64% to -$5.5 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.5 million, -$10.9 million, and -$649994.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Valneva SE 578.54 Mn 437.28 Mn 1.86 Mn 33.92 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 33.92 Mn
Mar 31, 2026 -5.49 Mn
Dec 31, 2025 -10.90 Mn
Sep 30, 2025 -649,994.63
Jun 30, 2025 16.84 Mn
Mar 31, 2025 -5.87 Mn
Dec 31, 2024 -4.90 Mn
Sep 30, 2024 56.95 Mn
Jun 30, 2024 -9.83 Mn
Mar 31, 2024 -8.10 Mn
Dec 31, 2023 39.75 Mn
Sep 30, 2023 10.34 Bn
Jun 30, 2023 -10.31 Bn
Mar 31, 2023 -4.10 Mn
Dec 31, 2022 95.38 Mn
Sep 30, 2022 16.76 Mn
Jun 30, 2022 111.00 Mn
Mar 31, 2022 1.10 Mn
Dec 31, 2021 91.37 Mn
Sep 30, 2021 -4.85 Mn